OPB 101
Alternative Names: OPB-101Latest Information Update: 13 Jun 2024
At a glance
- Originator Outpace Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Apr 2024 Outpace Bio intends to submit an IND application for OPB 101 in the fourth quarter of 2024
- 18 Jan 2024 OPB 101 is available for licensing as of 18 Jan 2024. https://www.outpacebio.com/connect#lets-collab